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ABSTRACT
Background: Delays in initiating elective inpatient chemotherapy can decrease patient satisfaction and
increase length of stay. At our institution, we observed that 86% of patients admitted for elective
chemotherapy experienced a delay (greater than 6 hours) with a median time to chemotherapy of 18.9
hours. We developed a process improvement initiative to improve time to chemotherapy for elective
chemotherapy admissions.
Methods: Our outcome measure was time from admission to chemotherapy administration in patients
admitted for elective chemotherapy. Process measures were identified and monitored. We collected
baseline data and utilized performance improvement tools to identify key drivers. We focused on these
key drivers to develop multiple plan-do-study-act (PDSA) cycles to improve our outcome measure. Once
we started an intervention we collected data every two weeks to assess our intervention.
Results: At the time of interim analysis, we observed a median decrease in time to chemotherapy
administration from 18.9 hours to 8.85 hours (p value:0.005). Median time to lab resulted decreased from
3.17 hours to 0.00 hours. There was no change in time from signature to nurse releasing the
chemotherapy. We noticed more providers were signing the chemotherapy prior to patient admission.
Conclusions: By implementing new admission workflows, optimizing our use of the Electronic Medical
Record to communicate among providers, and improving pre-admission planning we were able to reduce
our median time to chemotherapy for elective admissions by 53.2%. Improvement still needed to meet
our goals and to ensure sustainability of these ongoing efforts.

Introduction
Patients admitted to the hospital for elective chemotherapy are medically stable, however, numerous
processes can cause delays in initiating chemotherapy[1]. These delays lead to wasted time for the patient,
decreased patient satisfaction, and unnecessary prolonged length of stay (LOS)[2, 3]. While few studies
have evaluated improvement in the inpatient setting[1, 4], in the outpatient setting, studies have shown that
decreasing wait times can impact the quality of care and improve patient satisfaction.[5-7] In addition to
improving patient satisfaction with decreased wait times, decreasing length of stay may reduce hospital
related complications[8-10] and cost of care, not to mention reduce resource utilization.[11, 12]
As a result, using Institute for Healthcare Improvement model for improvement[13] and as part of the
American Society of Clinical Oncology quality training program, we developed a new workflow to
decrease time to chemotherapy administration in patients admitted electively to an oncology unit.
Quality Improvement (QI) Initiatives at our institution do not require IRB approval, but are submitted to
our institutional QI registry database.
Methods
A multidisciplinary team of physicians, pharmacists, nurses, administrators, information technology
analysts, pharmacy technicians, and physician assistants participated in discussions and implementation
of new processes. We defined a delay in chemotherapy as greater than 6 hours. This definition was based
on an informal discussion with patients and physicians regarding an acceptable time for chemotherapy
initiation. Time from admission to chemotherapy was defined as time of initial vital signs (best
documentation of when the patient arrived on the unit) until time of chemotherapy administration. Length
of stay was calculated using time of initial vitals to time of discharge. Other process measure endpoints
were determined by EPIC timestamps.

Aim Statement
We aimed to reduce the time from admission to initiation of chemotherapy by 68.3%, from a median of
18.9 hours to a median of 6 hours over 6 months from April to October, 2017.

Plan
A process map was developed (Appendix Figure 1). For baseline analysis, we reviewed charts for
patients electively admitted for chemotherapy during the month of February, 2017 (24 cases). We
measured time from admission to chemotherapy for each elective admission. Other key process measures
were identified and median times for each process were calculated (Appendix Figure 2). Chemotherapy
regimen type did not affect time to chemotherapy (Appendix Figure 3). Data were analyzed using QI
macros software (QIMacros, Denver, CO).
Do
Using QI tools such as a fishbone diagram[14] and Pareto Chart [15], we identified several processes causing
delays in initiating chemotherapy. We then constructed a PICK chart (Figure 1), to determine our
interventions: Improve communication between physician and nurses concerning signing of
chemotherapy, draw labs prior to admission, and improve time to chemotherapy signature.
1) The first intervention was implemented on 6/22/17. A column in EPIC was added to the nurses’
multi-provider screen so they could visualize when the chemotherapy had been signed.
2) The second intervention started on 7/19/17. Patients who arrived at the hospital prior to 4pm
would have their labs drawn prior to admission.
3) The third intervention started on 7/28/17. Physicians were notified to sign chemotherapy prior to
their patient’s admission.

Study
Data after each Plan-Do-Study-Act (PDSA) [16] implementation was collected from 6/22/17 to 10/30/17 at
2 week intervals. P values were calculated using two tailed t-tests.
Act
After reviewing data from the first intervention in mid July 2017, we decided to make a change to the
intervention. In addition to communication facilitated through the Electronic Medical Record (EMR), we
also discussed all new elective admissions at interdisciplinary rounds. At the same time we were
developing our new workflow to have labs drawn prior to admission. On 7/19/17 all patients who arrived
for admission prior to 4pm had labs drawn prior to registering for admission. This resulted in an
immediate reduction in time to labs resulted and this intervention was adopted as part of our standard
workflow. Our last intervention implemented on 7/28/17. This intervention helped improve our time to
chemotherapy and was adopted.
Results

Patient characteristics at baseline and for each PDSA cycle are listed in the appendix (Appendix -Table
1). Median time from admission to initiating chemotherapy was 18.9 hours. Median times for each step in
the process were also calculated (Appendix – Figure 2).
Our first PDSA cycle period (15 admissions – Appendix Table 1) resulted in no change in time from
signature to nurse releasing chemotherapy. Time to chemotherapy for this PDSA was 21.9 hours
Our second PDSA cycle period (7 admissions - Appendix Table 1), resulted in a decrease from time of
admission to labs resulted from a median: 3.17 hrs (n=38) to 0.00 hours (n=7) (Appendix Figure 4).
Median time to chemotherapy for this PDSA was 24.9 hours.

Our third PDSA cycle period (50 admissions- Appendix Table 1), resulted in an increase in chemotherapy
signatures prior to admission from 16% prior to the intervention (n=45) to 37% (n=50) after the
intervention. Median Time to chemotherapy for this PDSA was 8.85 hours.
Based on data from April to October 2017 the median time from admission to start of chemotherapy
decreased from 18.9 hours to 8.85 hours (p value: 0.005). Average LOS was 161.37 (SD: 141.59) hours at
baseline and 125.94 hours (SD: 82.34) after all 3 PDSA cycles were implemented – a 22% decrease in
LOS (p value: 0.2847).
Patients who were admitted for chemotherapy, but were not clinically stable were included in this analysis
(total cohort n=20). Many of the patients with significant delays over 36 hours fell into this subgroup
(n=8), with a median time to chemotherapy of 29.38 hours. Exclusion of these patients from the post
intervention group (n=4) still did not result in use reaching our goal of 6 hours (Median – 8.64 hours).
Discussion
Patient centered care is important in healthcare delivery and was the focus of this initiative. While we
were successful in decreasing our time to chemotherapy initiation by 53.2% at the time of this analysis,
we had not yet reached our goal (6 hours).
In our cohort, our EMR based solution to improve communication was not as effective as we had hoped.
This may have been due a poor understanding of which EMR screens the nurses are utilizing most, or an
under-appreciation of the fact that nurses spend a significant amount of time in direct patient contact.
Changing the admission workflow to have patient’s labs drawn prior to arrival did not have an immediate
effect on time to chemotherapy, but we believe it contributed to the overall improvement. The slight
increase in time to chemotherapy during PDSA 1 and 2 was likely due to disruption in the normal
workflow as this can result in an initial worsening of outcome measures prior to seeing the improvement.
Since PDSA #2 was a key driver and the process measure improved dramatically, we moved on to the

next PDSA cycle. We focused on the process and key drivers as leading indicators, understanding that the
outcome measure, often considered a lagging indicator, would follow. Our third intervention included
signing chemotherapy prior to admission reinforcing the point that pre-preparation is an effective strategy.
Even though approaches have been made to transfer inpatient cancer care to the outpatient setting with
success[17, 18], this might not always be possible in the hematologic malignancy population given
complexity of treatment regimen and need for close monitoring.
The major limitation to our study is that our data is from a single institution, however most process
improvement initiatives begin at single institutions prior to scaling it up across a healthcare network. We
included all patients that were admitted electively, including those who were not clinically stable for
chemotherapy. Including these patients impacted negatively on our initiation to chemotherapy time, but
doing so better reflects actual practice. Our next steps is to improve our pre-admission process to ensure
that all patients have appropriate IV access prior to arriving to the inpatient oncology unit and ensuring
that they are stable and ready to receive chemotherapy with a pre-admission telephone triage 24-hour
prior to admission. This has been successful in prior studies[5].
Another limitation of the study was inability to accurately measure LOS. Time of discharge is difficult to
determine in our EMR. As a result, we chose discontinuation of the vital signs order as a proxy for
discharge time as it was a consistent event across admissions. Our average length of stay decreased from
161.37 hours to 125.94 hours. In addition, the standard deviation narrowed from 141.59 hours to 82.34
suggesting that implementation of a more standardized workflow decreased variation from one admission
to another, which is an important component of a quality improvement initiative. One strength of this
intervention was our inter-professional collaboration. We had champions at all touch points in the process
making our PDSA cycles widely accepted.
In conclusion, by implementing new admission workflows, optimizing our use of the EMR to
communicate among providers, and improving pre-admission planning we were able to decrease time

from admission to initiation of chemotherapy by 53.2%. Further interventions are needed in order to
achieve our objective and standardize the processes.
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